biopharma

Discovering, developing and selling medicines. Companies selling tools and services to drug makers are life-sciences-tools and pharma-services.

Industry · 33 companies · 12 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • ABBV AbbVie

    Sells it 4%, $2.6B a year“AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies.”

    Latest 10-QQ3 FY2026Positive ·

    Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.

    • Revenue$17.4BYoY +10.3%
    • Net income$4.2Bvs $186.0M year ago
  • ADRX ADARx Pharmaceuticals, Inc.

    Sells it“We are a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops siRNA drugs for hereditary angioedema and other diseases; $446M all-primary raise funds clinical development

  • AMGN Amgen

    Sells it 100%, $36.8B a year“Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases.”

    Latest 10-QQ3 FY2026 ·

    Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.

    • Revenue$10.4BYoY +8.5%
    • Net income$3.9BYoY +20.1%
  • APMD Apnimed, Inc.

    In development“We are a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases.”

    Latest 424B4final IPO prospectusBankruptcy / going concernAccounting issueCEO/CFO change ·

    Develops Oxnimbi, a once-nightly sleep apnea pill; $192M all-primary raise funds regulatory work and launch if approved.

  • ARMP Armata Pharmaceuticals, Inc.

    Sells it“We are a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology.”

    Latest 10-QQ3 FY2026NegativeBankruptcy / going concern ·

    AP-SA02 advances toward Phase 3 with FDA support and expanded MTEC funding, but a cash shortfall threatens development.

    • Revenue$3.2MYoY +173.6%
    • Net income$54.9Mvs −$26.7M year ago
  • ASPE Aspen Neuroscience, Inc.

    Sells it“Aspen Neuroscience, Inc. is a leading, clinical-stage regenerative medicine biotechnology company focused on developing autologous iPSC-derived therapies to address neurodegenerative diseases with high unmet medical need.”

    Latest 424B4final IPO prospectusBankruptcy / going concernPre-revenue ·

    Develops patient-derived Parkinson’s cell therapy; $141M all-primary raise backs sasineprocel’s move toward Phase 3

  • ATTO Attovia Therapeutics, Inc.

    Sells it“We are a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops immune-disease biologics using ATTOBODY; $289M all-primary raise backs clinical validation of itch treatment ATTO-1310.

  • BBTX Bambusa Therapeutics, Inc.

    In development“We are a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation (“I&I”) and fundamentally improve patient quality of life.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernAccounting issueImpairment / charge ·

    Develops dual-target antibodies for eczema and respiratory diseases; $169M raise funds trials of BBT001 and BBT002.

  • BLSM BlossomHill Therapeutics, Inc.

    Sells it“We are a clinical-stage biopharmaceutical company applying our intentional, chemistry-based approach to develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment.”

    Latest 424B4final IPO prospectusBankruptcy / going concernPre-revenue ·

    Develops small-molecule cancer drugs; $150M all-primary raise funds trials led by BH-30643 for treatment-resistant lung cancer.

  • BMY Bristol-Myers Squibb

    Sells it 100%, $48.2B a year“We operate in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases.”

    Latest 10-QQ3 FY2026MixedImpairment / charge ·

    Eliquis drove growth as generics eroded Revlimid and Pomalyst; pipeline licensing charges weighed on earnings.

    • Revenue$13.1BYoY +6.9%
    • Net income$2.2BYoY −1.8%
  • BRVE Braveheart Bio, Inc.

    Sells it“We are a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases.”

    Latest 424B4final IPO prospectusPositiveImpairment / chargePre-revenueRelated-party dependence ·

    Develops BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy; $383M all-primary raise funds Phase 3 trials.

  • CAPR CAPRICOR THERAPEUTICS, INC.

    In development“Capricor is a clinical-stage biotechnology company developing cell- and exosome-based therapies, including Deramiocel for Duchenne muscular dystrophy (DMD).”

    Latest 10-QQ3 FY2026NegativeRestructuring ·

    Deramiocel’s FDA bid narrows to upper-limb impairment after an adverse cardiac efficacy vote; a Nippon Shinyaku dispute complicates launch plans.

    • Revenue$0vs $0 year ago
    • Net income−$42.7MYoY −73.6%
  • CTY CITY THERAPEUTICS, INC.

    Sells it“We are a clinical-stage biotechnology company developing the next generation of RNA interference (“RNAi”) therapeutics designed to silence the expression of disease-relevant proteins, with the aim of delivering meaningful, durable benefits for patients in need.”

    Latest 424B4final IPO prospectusCustomer concentration ·

    Develops RNA interference drugs led by CITY-FXI for thrombosis; raises $200M entirely through new shares.

  • DHR Danaher Corporation

    Supplies it 28%, $1.8B a quarter“Core sales grew 5.0%, led by bioprocessing consumables and improving equipment demand;”

    Latest 8-KPositiveEarningsGuidance raised ·

    Improving end markets accelerated core growth outside respiratory testing; FY2026 adjusted EPS guidance rose to $8.57–$8.62.

  • ETRA Electra Therapeutics, Inc.

    Sells it“We are a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernPre-revenue ·

    Develops antibodies to remove disease-driving immune cells; $350M all-primary raise funds ipsoprubart’s registrational trials

  • GILD Gilead Sciences

    Sells it 94%, $7.8B a quarter“Q3 revenue grew 7%, led by HIV products and Trodelvy.”

    Latest 10-QQ3 FY2026Impairment / charge ·

    Acquisition charges and the EVOKE-03 write-off drove a YTD loss despite stronger Biktarvy and Yeztugo sales.

    • Revenue$8.3BYoY +6.8%
    • Net income$2.4BYoY −20.4%
  • IAM Iambic Therapeutics, Inc.

    In development“We are advancing a pipeline of wholly owned drug candidates (Figure 14) developed using our molecular superintelligence platform.”

    Latest 424B4final IPO prospectusPositivePre-revenueCustomer concentration ·

    AI-driven drug developer raises $150M to advance lead HER2 cancer candidate IAM1363 and its pipeline

  • INVA Innoviva, Inc.

    Sells it 99%, $408.0M a year“Innoviva, Inc. (“Innoviva”, the “Company”, the “Registrant” or “we” and other similar pronouns) is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic healthcare assets.”

    Latest 10-QQ3 FY2026Positive ·

    XACDURO and GIAPREZA lift U.S. hospital sales; Armata markdowns overwhelm stronger operating earnings

    • Revenue$106.1MYoY −1.6%
    • Net income−$73.9Mvs $89.9M year ago
  • JNJ Johnson & Johnson

    Sells it 64%, $60.4B a year“Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.”

    Latest 10-QQ3 FY2026MixedRestructuringImpairment / chargeLegal / investigation ·

    TREMFYA and oncology growth offset STELARA’s biosimilar erosion, but a proposed talc-settlement charge nearly wiped out earnings.

    • Revenue$25.4BYoY +5.9%
    • Net income$210.0MYoY −95.9%
  • LLY Eli Lilly and Company

    Sells it 100%, $65.2B a year“We discover, develop, manufacture, and market products in a single business segment—human pharmaceutical products.”

    Latest 10-QQ3 FY2026PositiveImpairment / charge ·

    Mounjaro and Zepbound volume growth outweighed lower prices, while acquired research charges constrained profit growth.

    • Revenue$24.4BYoY +38.6%
    • Net income$6.5BYoY +15.5%
  • LTGO Latigo Biotherapeutics, Inc.

    Sells it“We are a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernAccounting issuePre-revenue ·

    Develops oral Nav1.8 non-opioid pain drugs; $346M all-primary raise backs LTG-001 pivotal trials and LTG-321 chronic-pain studies.

  • LYCA Lycia Therapeutics, Inc.

    In development“We are a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases.”

    Latest 424B4final IPO prospectusMixedPre-revenue ·

    Develops protein degraders for food allergy and Graves’ disease; raises $318M gross to advance clinical trials.

  • MRK Merck & Co.

    Sells it 74%, $48.0B a year“Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders.”

    Latest 8-KLeadership change ·

    Douglas M. Baker Jr. succeeds Thomas H. Glocer as independent lead director Jan. 1, 2027, ahead of Glocer’s May 2027 board retirement.

  • NUOX NuvOx Therapeutics, Inc.

    In development“We are a clinical-stage biopharmaceutical company developing innovative oxygen therapeutic solutions for the treatment of diseases where hypoxia, or lack of oxygen, plays a critical role.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernRestatementAccounting issue ·

    Intravenous oxygen drug developer seeks $20M gross at IPO midpoint to advance NanO₂ trials, with glioblastoma results the next major test

  • PFE Pfizer

    Sells it 85%, $53.3B a year“Most of our revenues come from the manufacture and sale of biopharmaceutical products.”

    Latest 8-KCEO/CFO change ·

    Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.

  • REGN Regeneron Pharmaceuticals

    Sells it 94%, $4.8B a quarter“Global product sales provide additional context but are not all recorded as Regeneron revenue: Sanofi records Dupixent sales and Regeneron receives a profit share; Regeneron records U.S. EYLEA sales while Bayer records ex-U.S. sales and shares profits.”

    Latest 10-QQ3 FY2026Positive ·

    Dupixent growth and richer Sanofi profit sharing more than offset EYLEA erosion, deepening reliance on the partnership.

    • Revenue$5.1BYoY +36.3%
    • Net income$1.9BYoY +33.5%
  • RZRA Rezera Inc.

    In development“We are a clinical-stage biotechnology company developing a portfolio of internally invented, proprietary and wholly owned oral inhibitors of NLRP3.”

    Latest S-1/Aamended IPO prospectusBankruptcy / going concernAccounting issueCEO/CFO change ·

    Develops oral anti-inflammatory drugs; IPO funds a pivotal ruvonoflast trial in peripheral artery disease, its first test in these patients.

  • SCTX Scribe Therapeutics, Inc.

    Sells it“We are a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernCustomer concentration ·

    Develops CRISPR medicines to lower cholesterol; $129M all-primary raise funds STX-1150 trials and pipeline development.

  • SDGR Schrödinger, Inc.

    In development“In addition, we use our computational platform to discover novel molecules for our pipeline of proprietary drug discovery programs, which we are advancing through preclinical and clinical development.”

    Latest 10-QQ3 FY2026 ·

    Structure Therapeutics milestone drove revenue growth; hosted migration obscured stronger software contracting.

    • Revenue$64.5MYoY +18.7%
    • Net income−$37.7MYoY −15.0%
  • STA Starton Holdings, Inc.

    In development“We are a clinical-stage biotechnology company focused on improving standard-of-care therapies for people with cancer through application of our proprietary platform of delivery technology systems.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issuePre-revenue ·

    Develops continuous-delivery lenalidomide for blood cancers; offering funds trials but further capital is needed to reach approval

  • VOGX Vogenx, Inc.

    In development“We are a clinical-stage life science and drug development company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernRestatementAccounting issue ·

    Developing oral mizagliflozin for post-bariatric hypoglycemia; $81.3M gross raise funds Phase 2 trials.

  • VRTX Vertex Pharmaceuticals

    Sells it 100%, $3.4B a quarter“Vertex has one pharmaceutical operating segment.”

    Latest 10-QQ3 FY2026Positive ·

    Crinetics adds an endocrine franchise, but deal costs and launch spending squeeze profit despite ALYFTREK-led sales growth.

    • Revenue$3.4BYoY +11.8%
    • Net income$653.6MYoY −39.6%
  • WWB WINDWARD BIO GROUP AG

    Sells it“We are a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops long-acting antibodies for asthma and other inflammatory diseases; $175M raise funds trials led by WIN378’s potential twice-yearly dosing

Feedback